CN117355507A - 用作lrrk2激酶抑制剂的嘧啶衍生物 - Google Patents

用作lrrk2激酶抑制剂的嘧啶衍生物 Download PDF

Info

Publication number
CN117355507A
CN117355507A CN202280036432.0A CN202280036432A CN117355507A CN 117355507 A CN117355507 A CN 117355507A CN 202280036432 A CN202280036432 A CN 202280036432A CN 117355507 A CN117355507 A CN 117355507A
Authority
CN
China
Prior art keywords
compound
group
membered
disease
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280036432.0A
Other languages
English (en)
Chinese (zh)
Inventor
大卫·J·比尔斯
约翰·世强·考韦三世
亚历克西斯·亨利·阿贝尔·莫拉德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Halia Treatment Co
Original Assignee
Halia Treatment Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Halia Treatment Co filed Critical Halia Treatment Co
Publication of CN117355507A publication Critical patent/CN117355507A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN202280036432.0A 2021-03-23 2022-03-23 用作lrrk2激酶抑制剂的嘧啶衍生物 Pending CN117355507A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163164804P 2021-03-23 2021-03-23
US63/164,804 2021-03-23
PCT/US2022/021573 WO2022204299A1 (en) 2021-03-23 2022-03-23 Pyrimidine derivatives useful as lrrk2 kinase inhibitors

Publications (1)

Publication Number Publication Date
CN117355507A true CN117355507A (zh) 2024-01-05

Family

ID=81328290

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280036432.0A Pending CN117355507A (zh) 2021-03-23 2022-03-23 用作lrrk2激酶抑制剂的嘧啶衍生物

Country Status (12)

Country Link
US (4) US11578061B2 (cg-RX-API-DMAC10.html)
EP (1) EP4313955A1 (cg-RX-API-DMAC10.html)
JP (1) JP2024512024A (cg-RX-API-DMAC10.html)
KR (1) KR20230170684A (cg-RX-API-DMAC10.html)
CN (1) CN117355507A (cg-RX-API-DMAC10.html)
AU (1) AU2022246081A1 (cg-RX-API-DMAC10.html)
BR (1) BR112023019388A2 (cg-RX-API-DMAC10.html)
CA (1) CA3214360A1 (cg-RX-API-DMAC10.html)
CO (1) CO2023012903A2 (cg-RX-API-DMAC10.html)
IL (1) IL306008A (cg-RX-API-DMAC10.html)
MX (1) MX2023011027A (cg-RX-API-DMAC10.html)
WO (1) WO2022204299A1 (cg-RX-API-DMAC10.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2022246081A1 (en) * 2021-03-23 2023-10-12 Halia Therapeutics, Inc. Pyrimidine derivatives useful as lrrk2 kinase inhibitors

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103038230A (zh) * 2010-06-04 2013-04-10 霍夫曼-拉罗奇有限公司 作为lrrk2调节剂的氨基嘧啶衍生物
CN103313978A (zh) * 2010-11-10 2013-09-18 霍夫曼-拉罗奇有限公司 作为lrrk2调节剂的吡唑氨基嘧啶衍生物
CN105801493A (zh) * 2011-11-29 2016-07-27 霍夫曼-拉罗奇有限公司 作为激酶lrrk2调节剂用于治疗帕金森病的2-苯基氨基嘧啶衍生物
WO2017087905A1 (en) * 2015-11-20 2017-05-26 Denali Therapeutics Inc. Compound, compositions, and methods
WO2017156493A1 (en) * 2016-03-11 2017-09-14 Denali Therapeutics Inc. Compounds, compositions, and methods

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0619343D0 (en) 2006-09-30 2006-11-08 Vernalis R&D Ltd New chemical compounds
TW201024281A (en) 2008-11-24 2010-07-01 Boehringer Ingelheim Int New compounds
AU2010331927B2 (en) 2009-12-17 2013-10-10 Merck Canada Inc. Aminopyrimidines as Syk inhibitors
EP2512246B1 (en) 2009-12-17 2015-09-30 Merck Sharp & Dohme Corp. Aminopyrimidines as syk inhibitors
ES2665421T3 (es) 2013-06-04 2018-04-25 Acturum Real Estate Ab Compuestos de pirimidina y su uso como moduladores de la gamma secretasa
RU2016134751A (ru) * 2014-01-29 2018-03-02 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Соединения
US9879008B2 (en) 2014-04-14 2018-01-30 Shanghai Haiyan Pharmaceutical Technology Co., Ltd. 2,3,4,6-tetra-substituted benzene-1,5-diamine derivatives, preparation method therefor and medicinal use thereof
US11174248B2 (en) 2017-10-11 2021-11-16 Merck Sharp & Dohme Corp. Indazolyl-spiro[2.3]hexane-carbonitrile derivatives as LRRK2 inhibitors, pharmaceutical compositions, and uses thereof
CA3085561A1 (en) 2017-12-19 2019-06-27 Bristol-Myers Squibb Company Cyclohexyl acid triazole azines as lpa antagonists
CN110872277B (zh) 2019-11-14 2021-06-04 浙江大学 N-取代芳环-2-氨基嘧啶类化合物及用途
AU2022246081A1 (en) * 2021-03-23 2023-10-12 Halia Therapeutics, Inc. Pyrimidine derivatives useful as lrrk2 kinase inhibitors

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103038230A (zh) * 2010-06-04 2013-04-10 霍夫曼-拉罗奇有限公司 作为lrrk2调节剂的氨基嘧啶衍生物
CN103313978A (zh) * 2010-11-10 2013-09-18 霍夫曼-拉罗奇有限公司 作为lrrk2调节剂的吡唑氨基嘧啶衍生物
CN105801493A (zh) * 2011-11-29 2016-07-27 霍夫曼-拉罗奇有限公司 作为激酶lrrk2调节剂用于治疗帕金森病的2-苯基氨基嘧啶衍生物
WO2017087905A1 (en) * 2015-11-20 2017-05-26 Denali Therapeutics Inc. Compound, compositions, and methods
WO2017156493A1 (en) * 2016-03-11 2017-09-14 Denali Therapeutics Inc. Compounds, compositions, and methods

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ACS: "ACS.REGISTRY DATABASE,RN号1793840-00-2等", 《STNEXT》, 3 July 2015 (2015-07-03), pages 1 - 5 *

Also Published As

Publication number Publication date
MX2023011027A (es) 2023-09-27
KR20230170684A (ko) 2023-12-19
US12428404B2 (en) 2025-09-30
US11578061B2 (en) 2023-02-14
AU2022246081A1 (en) 2023-10-12
EP4313955A1 (en) 2024-02-07
US20240190848A1 (en) 2024-06-13
IL306008A (en) 2023-11-01
US11866423B2 (en) 2024-01-09
US20230183217A1 (en) 2023-06-15
JP2024512024A (ja) 2024-03-18
US20220324845A1 (en) 2022-10-13
CO2023012903A2 (es) 2023-10-09
US20260055087A1 (en) 2026-02-26
BR112023019388A2 (pt) 2023-11-07
WO2022204299A1 (en) 2022-09-29
CA3214360A1 (en) 2022-09-29

Similar Documents

Publication Publication Date Title
US11053239B2 (en) Compounds as BLC-2-selective apoptosis-inducing agents
CN115843272B (zh) Nek7激酶的抑制剂
KR20250020690A (ko) 세레블론(crbn)에 대한 리간드
US11459332B2 (en) Substituted 2-azabicyclo[3.1.0]hexanes as TRK kinases inhibitors
KR20230175222A (ko) Nek7 억제제
US7338957B2 (en) Compounds and compositions as protein kinase inhibitors
TWI752026B (zh) 一類蛋白激酶抑制劑
JP5124471B2 (ja) 置換二環式ピリミドン誘導体
US20260132158A1 (en) Phenyl oxy amide kinase inhibitors
CN108463222A (zh) 用于治疗疾病的杂环化合物
US20240400551A1 (en) Nek7 inhibitors
JP2023533616A (ja) Mnk阻害を示すピリジン-1,5-ジオン及びそれらの使用方法
US20260055087A1 (en) Inhibitors of lrrk2 kinase
JP6100755B2 (ja) (2−ヘテロアリールアミノ)コハク酸誘導体
JP2023504468A (ja) 焦点接着キナーゼ阻害剤としての新規なアダマンタン誘導体
US20250177382A1 (en) Nek7 inhibitors
CN117597346A (zh) Nek7抑制剂
US20250312335A1 (en) Flt combination therapy for cancer and compositions therefor
WO2023049270A1 (en) Pyrrole[2,3-b]pyridine derivatives as tyro3 inhibitors
BR112018072699B1 (pt) Compostos inibidores de proteína cinase, composição farmacêutica que os compreende e seus usos

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination